Dr.
Gary Mo received his Ph.D. in Neuroscience from McGill University. He
has many years of industrial collaboration and joined the AstraZeneca
sponsored PKPD postdoctoral program after his graduation. His current
work within the Center for Protein Therapeutics involves the
development of a mechanistic model to describe the changes in
regulation of granulopoiesis following chemotherapy induced
neutropenia. The model will describe the pharmacodynamic mediated
disposition of G-CSF and its effect on stimulation of neutrophil
production.
Balthasar Laboratory,
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The
State University of New York